Competing causes of death in patients with oropharyngeal cancer treated with radiotherapy
Open Access
- 23 February 2012
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 3 (5) , 835-840
Abstract
Radiation with or without chemotherapy is considered the mainstay of treatment for the majority of patients with oropharyngeal cancer. The goal of this study was to analyze competing causes of mortality in patients with oropharyngeal cancer with long-term follow-up. We queried the Surveillance, Epidemiology and End Results (SEER) database and identified 3728 patients with oropharyngeal cancer treated between 1988 and 2001 with definitive radiotherapy. We analyzed predictors of overall survival and risks of mortality from index oropharyngeal cancer, second primary cancer, cardiovascular disease and other causes using a cumulative incidence analysis and Cox multivariate analysis. With a median follow-up of 6.8 years, the 5- and 10‑year overall survival was 37 and 22%, respectively. At 5 years, the risk of mortality from primary oropharyngeal cancer was 35%. Between years 3 and 10, 69% of mortalities were attributed to causes other than the index cancer. Despite advances in the non-surgical treatment of oropharyngeal cancer, patients remain at significant risk of cancer- and non-cancer-related mortality.Keywords
This publication has 29 references indexed in Scilit:
- Predictors of Competing Mortality in Advanced Head and Neck CancerJournal of Clinical Oncology, 2010
- Adjuvant Radiotherapy and Survival for Patients With Node-Positive Head and Neck Cancer: An Analysis by Primary Site and Nodal StageInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck CancerNew England Journal of Medicine, 2007
- A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysisThe Lancet, 2006
- Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2006
- Tongue and tonsil carcinomaCancer, 2005
- Preliminary Results of Radiation Therapy Oncology Group 97-03: A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and NeckJournal of Clinical Oncology, 2004
- Final Results of the 94–01 French Head and Neck Oncology and Radiotherapy Group Randomized Trial Comparing Radiotherapy Alone With Concomitant Radiochemotherapy in Advanced-Stage Oropharynx CarcinomaJournal of Clinical Oncology, 2004
- A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000